Newsroom | 1438 results

DENVER--(BUSINESS WIRE)--Front Range Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for FRP-003, allowing the company to proceed with a Phase 2 clinical trial in adults with Long COVID. FDA notified the company in writing on September 30, 2026, that the study may proceed.The multicenter, randomized, double-blind, placebo-controlled Phase 2 study will enroll approximately 220 adults aged 18 to 6...

WASHINGTON--(BUSINESS WIRE)--The Independent Medical Alliance (IMA) today announced the publication of Volume 2, No. 5 of the Journal of Independent Medicine (JIM), continuing the journal’s growing international reach and its mission to advance rigorous, conflict-free scientific inquiry through collaboration among physicians, researchers, and experts from around the world. This latest issue reflects an increasingly global scientific community examining health challenges that extend far beyond n...

PHILADELPHIA--(BUSINESS WIRE)--Bleu Garde, LLC, a science and technology company developing next-generation indoor air treatment technologies for pathogen reduction, environmental health and pandemic preparedness, today announced at the Builds Bio+ 5th Annual Philadelphia Life Science Symposium that the U.S. Environmental Protection Agency (EPA) has registered Arresta® for use as a virucidal air treatment, air sanitizer and fungistat, including use in occupied indoor spaces in accordance with i...

FLORHAM PARK, N.J.--(BUSINESS WIRE)--Shionogi Inc., a New Jersey-based subsidiary of Shionogi & Co., Ltd., (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.), will present findings from across its broad anti-infective portfolio at IDWeek 2026 (October 21-24, 2026), in Washington, D.C. Data highlights at IDWeek 2026 include an oral presentation featuring a subpopulation analysis from the global Phase 3 SCORPIO-PEP trial, a rapid-fire session focused on ventilator-ass...

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the companies’ 2026-2027 COVID-19 vaccine formula targeting the XFG variant (COMIRNATY® XFG; COVID-19 Vaccine, mRNA) for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying con...

IRVINE, Calif.--(BUSINESS WIRE)--AIVITA Biomedical, Inc., a biotechnology company developing personalized vaccines for the prevention of infectious disease and treatment of cancer, today announced the appointment of renowned physician, epidemiologist, technologist, philanthropist, and author Larry Brilliant, M.D., M.P.H., to its board of directors. Dr. Brilliant brings globally recognized expertise in epidemiology, pandemic preparedness, and vaccine readiness that is especially relevant to AIVI...

NORTH BETHESDA, Md.--(BUSINESS WIRE)--The Foundation for the National Institutes of Health awards the 2026 Kovler Prize for Trust in Life Science Journalism to STAT's Helen Branswell....

FOSTER CITY, Calif.--(BUSINESS WIRE)--Please replace the release with the following corrected version due to a change in the "PRODUCT SALES SUMMARY" table, where the Odefsey sales in Europe have been updated to $58 million for the three months ended June 30, 2026 (instead of $28 million). The updated release reads: GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 10% Year-Over-Year to $7.6 billion Biktarvy Sales Increased 7% Year-Over-Yea...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2026 and raised its full-year 2026 Revenue guidance by $500 million at the midpoint while reaffirming guidance(2) for Adjusted(3) diluted EPS, which absorbs an impact of approximately $0.10 related to the Innovent Biologics, Inc. transaction. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: “Pfizer had another strong quarter, delivering on our financial commitments and adva...

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Commission (EC) has granted marketing authorization for the companies’ 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the Emergency Task Force (ETF) of the European Medic...